| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
YM-58790 primarily targets the muscarinic acetylcholine receptor (mAChR), with a particular affinity for the M3 subtype (Ki = 15 nM). It also binds to M1 (Ki = 28 nM) and M2 (Ki = 260 nM) isoforms. As an antagonist, it blocks the action of acetylcholine at these receptors, which are G protein-coupled receptors involved in various parasympathetic nervous system functions, including smooth muscle contraction and glandular secretion.
|
|---|---|
| ln Vitro |
YM-58790 (compound 18b) has a significant inhibitory effect on bladder contraction at concentrations of 0-1μM, but it has minimal effect on bradycardia. In vitro, YM-58790 demonstrates a specific antagonistic relationship between saliva secretion and bladder contraction [1].
In vitro, YM-58790 shows a potent inhibitory effect on urinary bladder contraction at concentrations of 0-1 microM but has a minimal effect on bradycardia. It exhibits a selective antagonistic relationship between salivary secretion and bladder contraction. The compound demonstrates a specific antagonistic profile, suggesting tissue-specific effects on muscarinic receptor subtypes. |
| ln Vivo |
Mice that have been given oxotremorine-induced tremor are not affected by YM-58790 (3 mg/kg, intravenous injection) [1]. In rat rats given McN-A343-induced hypertension, YM-58790 (6.0 mg/kg; iv) shows weak M1 and M2 antagonistic effects in vivo; however, it is highly effective against M3 antagonistic effects, with an ED30 value of 0.36 mg/kg (iv) and an ID50 value of 2.4 mg/kg (iv)[1]. YM-58790 is less inhibitory than oxybutynin on oxytremorine-induced salivation in rats approximately ten times[1], but it has strong inhibitory activity on bladder compression during reflex-induced rhythmic contractions.
In vivo, YM-58790 (3 mg/kg, i.v.) does not inhibit oxotremorine-induced tremor in mice. Its effect on McN-A343-induced pressor in pithed rats, an indication of M1 antagonism, is much less potent than its effect on bladder contraction. It exhibits potent inhibitory activity on bladder pressure in reflexly-evoked rhythmic contraction, similar to oxybutynin, but has approximately ten times less inhibitory effect on salivary secretion. |
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, YM-58790 can be evaluated using radioligand binding studies with membranes expressing human recombinant muscarinic receptor subtypes (M1, M2, M3). Competition binding experiments using a labeled muscarinic antagonist, such as [3H]-NMS, determine the compound's affinity (Ki) for each receptor. The assay is performed by incubating various concentrations of YM-58790 with the receptor membranes and radioligand, followed by filtration and scintillation counting to measure bound radioactivity.
|
| Cell Assay |
For in vitro cellular experiments, YM-58790 can be tested in cell lines expressing muscarinic receptor subtypes, such as CHO or HEK293 cells stably transfected with M1, M2, or M3 receptors. Cells are cultured in appropriate media and treated with various concentrations of the compound. Receptor-mediated signaling, such as calcium mobilization or IP1 accumulation, is measured to assess antagonism. Additionally, functional assays using isolated tissue preparations, like urinary bladder strips, can evaluate the compound's effect on smooth muscle contraction.
|
| Animal Protocol |
For in vivo animal experiments, YM-58790 can be administered to rats via intravenous injection to assess its effects on bladder function and other physiological parameters. In one study, a dose of 3 mg/kg was used to evaluate its effect on oxotremorine-induced tremor. Other models include pithed rats for assessing cardiovascular effects and reflexly-evoked rhythmic bladder contraction models to measure inhibitory activity on bladder pressure. Standard procedures for monitoring vital signs and tissue collection should be followed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of YM-58790 are not extensively detailed in the provided references. As a small molecule with a molecular weight of 466.01, it is likely to have reasonable bioavailability and tissue distribution. The compound is typically administered intravenously in animal studies. Further comprehensive PK studies, including parameters such as Cₘₐₓ, Tₘₐₓ, AUC, half-life, and clearance, would be needed to fully characterize its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for YM-58790 are limited in the provided references. As a research compound, comprehensive toxicology studies, including acute and repeated-dose toxicity, genotoxicity, and cardiotoxicity (hERG) assessments, would be required for further development. The compound is for research use only and is not intended for human therapeutic use. Appropriate safety precautions should be taken when handling this compound, including the use of personal protective equipment.
|
| References | |
| Additional Infomation |
YM-58790 is a research compound primarily used to study muscarinic receptor function, particularly in the context of bladder function and respiratory inflammation. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. YM-58790 was described in a study on selective muscarinic antagonists, specifically 4-piperidyl benzhydrylcarbamate derivatives.
|
| Molecular Formula |
C27H32CLN3O2
|
|---|---|
| Molecular Weight |
466.0149
|
| Exact Mass |
465.218
|
| CAS # |
214558-72-2
|
| Related CAS # |
YM-58790 free base;168830-70-4
|
| PubChem CID |
129010504
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
33
|
| Complexity |
525
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CNC1=CC=C(C=C1)CN2CCC(CC2)OC(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4.Cl
|
| InChi Key |
WKHYQXVQUGLLOZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H31N3O2.ClH/c1-28-24-14-12-21(13-15-24)20-30-18-16-25(17-19-30)32-27(31)29-26(22-8-4-2-5-9-22)23-10-6-3-7-11-23;/h2-15,25-26,28H,16-20H2,1H3,(H,29,31);1H
|
| Chemical Name |
[1-[[4-(methylamino)phenyl]methyl]piperidin-4-yl] N-benzhydrylcarbamate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~214.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1459 mL | 10.7294 mL | 21.4588 mL | |
| 5 mM | 0.4292 mL | 2.1459 mL | 4.2918 mL | |
| 10 mM | 0.2146 mL | 1.0729 mL | 2.1459 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
